253 related articles for article (PubMed ID: 29988125)
1. Verapamil and beta cell function in adults with recent-onset type 1 diabetes.
Ovalle F; Grimes T; Xu G; Patel AJ; Grayson TB; Thielen LA; Li P; Shalev A
Nat Med; 2018 Aug; 24(8):1108-1112. PubMed ID: 29988125
[TBL] [Abstract][Full Text] [Related]
2. Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial.
Forlenza GP; McVean J; Beck RW; Bauza C; Bailey R; Buckingham B; DiMeglio LA; Sherr JL; Clements M; Neyman A; Evans-Molina C; Sims EK; Messer LH; Ekhlaspour L; McDonough R; Van Name M; Rojas D; Beasley S; DuBose S; Kollman C; Moran A;
JAMA; 2023 Mar; 329(12):990-999. PubMed ID: 36826844
[TBL] [Abstract][Full Text] [Related]
3. Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes.
Xu G; Grimes TD; Grayson TB; Chen J; Thielen LA; Tse HM; Li P; Kanke M; Lin TT; Schepmoes AA; Swensen AC; Petyuk VA; Ovalle F; Sethupathy P; Qian WJ; Shalev A
Nat Commun; 2022 Mar; 13(1):1159. PubMed ID: 35241690
[TBL] [Abstract][Full Text] [Related]
4. Verapamil Prevents Decline of IGF-I in Subjects With Type 1 Diabetes and Promotes β-Cell IGF-I Signaling.
Xu G; Chen J; Lu B; Sethupathy P; Qian WJ; Shalev A
Diabetes; 2023 Oct; 72(10):1460-1469. PubMed ID: 37494660
[TBL] [Abstract][Full Text] [Related]
5. Verapamil and Pancreatic Beta Cell Function in Pediatric Type 1 Diabetes.
Hsu NC; Tsai HB; Hsu CH
JAMA; 2023 Jul; 330(4):380. PubMed ID: 37490090
[No Abstract] [Full Text] [Related]
6. Verapamil and Pancreatic Beta Cell Function in Pediatric Type 1 Diabetes-Reply.
Forlenza GP; Schamberger MS; Buckingham BA
JAMA; 2023 Jul; 330(4):380. PubMed ID: 37490087
[No Abstract] [Full Text] [Related]
7. A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Alpha-1 Antitrypsin (AAT) (Glassia
Lebenthal Y; Brener A; Hershkovitz E; Shehadeh N; Shalitin S; Lewis EC; Elias D; Haim A; Barash G; Loewenthal N; Zuckerman-Levin N; Stein M; Tov N; Rachmiel M
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795482
[TBL] [Abstract][Full Text] [Related]
8. An improved clinical model to predict stimulated C-peptide in children with recent-onset type 1 diabetes.
Buchanan K; Mehdi AM; Hughes I; Cotterill A; Le Cao KA; Thomas R; Harris M
Pediatr Diabetes; 2019 Mar; 20(2):166-171. PubMed ID: 30556344
[TBL] [Abstract][Full Text] [Related]
9. Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension.
Muijsers RB; Curran MP; Perry CM
Drugs; 2002; 62(17):2539-67. PubMed ID: 12421112
[TBL] [Abstract][Full Text] [Related]
10. Diabetes pathogenic mechanisms and potential new therapies based upon a novel target called TXNIP.
Thielen L; Shalev A
Curr Opin Endocrinol Diabetes Obes; 2018 Apr; 25(2):75-80. PubMed ID: 29356688
[TBL] [Abstract][Full Text] [Related]
11. Cell type-specific immune phenotypes predict loss of insulin secretion in new-onset type 1 diabetes.
Dufort MJ; Greenbaum CJ; Speake C; Linsley PS
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830868
[TBL] [Abstract][Full Text] [Related]
12. Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual β-cell function in recent-onset type 1 diabetes.
Demeester S; Keymeulen B; Kaufman L; Van Dalem A; Balti EV; Van de Velde U; Goubert P; Verhaeghen K; Davidson HW; Wenzlau JM; Weets I; Pipeleers DG; Gorus FK
Diabetes Care; 2015 Apr; 38(4):644-51. PubMed ID: 25583753
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of long-term treatment effect in a type 1 diabetes intervention trial: differences after stimulation with glucagon or a mixed meal.
Pozzilli P; Raz I; Peled D; Elias D; Avron A; Tamir M; Eren R; Dagan S; Cohen IR
Diabetes Care; 2014; 37(5):1384-91. PubMed ID: 24408401
[TBL] [Abstract][Full Text] [Related]
14. β-Cell Glucose Sensitivity to Assess Changes in β-Cell Function in Recent-Onset Stage 3 Type 1 Diabetes.
Gitelman SE; Evans-Molina C; Guolo A; Mari A; Ferrannini E
Diabetes; 2023 Sep; 72(9):1289-1296. PubMed ID: 37368990
[TBL] [Abstract][Full Text] [Related]
15. Serum miR-204 is an early biomarker of type 1 diabetes-associated pancreatic beta-cell loss.
Xu G; Thielen LA; Chen J; Grayson TB; Grimes T; Bridges SL; Tse HM; Smith B; Patel R; Li P; Evans-Molina C; Ovalle F; Shalev A
Am J Physiol Endocrinol Metab; 2019 Oct; 317(4):E723-E730. PubMed ID: 31408375
[TBL] [Abstract][Full Text] [Related]
16. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.
Rigby MR; Harris KM; Pinckney A; DiMeglio LA; Rendell MS; Felner EI; Dostou JM; Gitelman SE; Griffin KJ; Tsalikian E; Gottlieb PA; Greenbaum CJ; Sherry NA; Moore WV; Monzavi R; Willi SM; Raskin P; Keyes-Elstein L; Long SA; Kanaparthi S; Lim N; Phippard D; Soppe CL; Fitzgibbon ML; McNamara J; Nepom GT; Ehlers MR
J Clin Invest; 2015 Aug; 125(8):3285-96. PubMed ID: 26193635
[TBL] [Abstract][Full Text] [Related]
17. Generation of stem cell-derived β-cells from patients with type 1 diabetes.
Millman JR; Xie C; Van Dervort A; Gürtler M; Pagliuca FW; Melton DA
Nat Commun; 2016 May; 7():11463. PubMed ID: 27163171
[TBL] [Abstract][Full Text] [Related]
18. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial.
Raz I; Elias D; Avron A; Tamir M; Metzger M; Cohen IR
Lancet; 2001 Nov; 358(9295):1749-53. PubMed ID: 11734230
[TBL] [Abstract][Full Text] [Related]
19. Clinical and metabolic characteristics of patients with latent autoimmune diabetes in adults (LADA): absence of rapid beta-cell loss in patients with tight metabolic control.
Chaillous L; Bouhanick B; Kerlan V; Mathieu E; Lecomte P; Ducluzeau PH; Delamaire M; Sonnet E; Maugendre D; Maréchaud R; Rohmer V; Saï P; Charbonnel B
Diabetes Metab; 2010 Feb; 36(1):64-70. PubMed ID: 20060765
[TBL] [Abstract][Full Text] [Related]
20. Testing a new platform to screen disease-modifying therapy in type 1 diabetes.
Lord SM; Bahnson HT; Greenbaum CJ; Liljenquist DR; Virostko J; Speake C
PLoS One; 2023; 18(12):e0293268. PubMed ID: 38096190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
